S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.19
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.52
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
16.68
-0.63
-3.64%
XENE · Xenon Pharmaceuticals Inc. Common Shares
NASDAQ NMS - GLOBAL MARKET - BOATS Real Time Price • USD
Xenon Pharmaceuticals Inc (XENE)
NASDAQ NMS - GLOBAL MARKET
Biotechnology
$35.98
-0.28
(-0.77%)
● At close: October 21 at 4:00:00 PM EDT
$35.65
-0.30
(-0.83%)
Overnight:
12:05:50 AM EDT
DAY'S RANGE
$35.98
$35.91
$36.74
52-WEEK RANGE
$35.98
$33.38
$72.66
What's happening
- XENE is down 0.77% today, trading at $35.98. — Live quote
- Volume today (39,132) is well below its 3-month average of 1,527,550. (Finnhub fundamentals)
- Reports earnings on 2026-11-11 (after market close), 20 days away. (Finnhub earnings calendar)
- Last quarter's EPS beat estimates: $-1.11 actual vs. $-1.16 estimated (+4.4%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 11
Buy 13
Hold 2
Sell 0
Strong sell 0
Aggregate ratings for 2026-10-01 (26 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
XENE
-19.08%
vs S&P 500
-31.85%
1-YEAR RETURN
XENE
-16.51%
vs S&P 500
-31.07%
6-MONTH RETURN
XENE
-37.93%
3-MONTH RETURN
XENE
-45.65%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-1.11
Est. $-1.16
BEAT +4.4%
2026-04-26 (Q1 2026)
$-1.17
Est. $-1.21
BEAT +3.1%
2026-01-26 (Q4 2025)
$-1.31
Est. $-1.22
MISS -7.8%
2025-10-26 (Q3 2025)
$-1.15
Est. $-1.18
BEAT +2.1%
Valuation Measures & Ratios
Enterprise Value4$3.28B
Forward P/E5—
PEG Ratio6-0.30
Price / Sales (TTM1)453.30
Price / Book74.70
EV4 / Revenue437.36
EV4 / EBITDA—
Profit Margin-867.29%
Operating Margin-969.84%
Return on Equity (ROE8)-43.98%
Return on Assets (ROA9)-41.72%
Avg Volume (3M)1,527,550
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $6.02B | $5.08B | $3.17B | $2.48B | $2.63B |
| P/E | -15.49 | -14.82 | -10.46 | -9.17 | -11.26 |
| Price/Book | 4.85 | 3.80 | 5.67 | 3.91 | 3.74 |
| ROE | -31.28% | -25.64% | -54.23% | -42.66% | -33.20% |
| ROA | -29.99% | -24.73% | -49.92% | -40.11% | -31.44% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short6,041,487
Change from Prior Settlement-6.26%
% of Float—
Days to Cover (Short Ratio)1.58
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Latest SEC filing is Form 4, filed 2026-10-16; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Revenue growth is -25.3% on the provider's reported measure. Finnhub fundamentals ↗
- Net profit margin is -867.3%. Finnhub fundamentals ↗
- Trailing 52-week price return is -16.5%. Finnhub market metrics ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on XENE
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Operating income | -$123.2M | -$112.3M | -$96.3M | -$94.2M | -$72.7M | -$73.7M | -$69.1M | -$59.0M |
| Net income | -$110.7M | -$102.3M | -$90.9M | -$84.7M | -$65.0M | -$62.8M | -$57.9M | -$47.9M |
| EPS (diluted) | $-1.11 | $-1.17 | $-1.15 | $-1.07 | $-0.83 | $-0.81 | $-0.75 | $-0.62 |
| EPS (basic) | $-1.11 | $-1.17 | $-1.15 | $-1.07 | $-0.83 | $-0.81 | $-0.75 | $-0.62 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $1.30B | $1.39B | $633.2M | $607.8M | $674.3M | $743.3M | $798.1M | $835.9M |
| Total liabilities | $53.4M | $49.0M | $51.4M | $48.3M | $40.3M | $39.3M | $43.2M | $38.1M |
| Stockholders' equity | $1.24B | $1.34B | $581.8M | $559.5M | $634.0M | $704.0M | $754.9M | $797.8M |
| Total current assets | $945.9M | $1.11B | $560.6M | $480.1M | $500.3M | $565.5M | $635.3M | $659.6M |
| Total current liabilities | $45.0M | $39.8M | $41.8M | $38.3M | $33.0M | $32.0M | $35.6M | $29.7M |
| Cash & equivalents | $119.5M | $545.9M | $199.2M | $104.5M | $135.4M | $116.7M | $142.7M | $87.6M |
| Marketable securities (current) | $811.2M | $548.9M | $349.7M | $357.8M | $352.2M | $433.0M | $484.2M | $566.4M |
| Accounts receivable | — | — | — | — | — | — | $1.5M | $938.0K |
| Marketable securities (non-current) | $314.4M | $244.9M | $37.2M | $93.0M | $137.3M | $141.5M | $127.5M | $149.3M |
| Property, plant & equipment | $7.8M | $8.3M | $8.7M | $8.9M | $9.2M | $9.7M | $10.3M | $10.2M |
| Accrued liabilities | $41.2M | $32.5M | $36.4M | — | — | — | — | — |
| Deferred revenue (current) | — | — | — | — | — | — | — | — |
| Short-term debt | — | — | — | — | — | — | — | — |
| Long-term debt | — | — | — | — | — | — | — | — |
| Other non-current liabilities | $3.3M | $3.2M | $3.2M | $3.2M | — | — | $0 | — |
| Common stock & paid-in capital | $2.43B | $2.42B | $1.60B | $1.48B | $1.47B | $1.46B | $1.46B | $1.44B |
| Retained earnings | -$1.46B | -$1.35B | -$1.25B | -$1.14B | -$1.05B | -$964.5M | -$899.5M | -$833.8M |
| Accumulated other comprehensive income (loss) | -$2.7M | -$1.2M | $335.0K | $477.0K | $113.0K | -$836.0K | -$1.6M | $1.3M |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$95.4M | -$88.9M | -$81.5M | -$71.8M | -$64.2M | -$61.7M | -$54.4M | -$49.7M |
| Investing cash flow | -$331.2M | -$407.3M | $62.7M | $38.5M | $82.3M | $34.5M | $98.5M | $498.0K |
| Financing cash flow | $26.0K | $843.0M | $113.5M | $2.4M | $65.0K | $1.2M | $12.1M | $0 |
| Free cash flow | -$95.7M | -$89.0M | -$81.8M | -$72.0M | -$64.4M | -$61.7M | -$55.2M | -$50.3M |
| Capital expenditures | $275.0K | $133.0K | $318.0K | $281.0K | $157.0K | $43.0K | $783.0K | $590.0K |
| Depreciation & amortization | — | — | — | — | — | — | — | — |
| Share-based compensation | $16.7M | $16.9M | $41.5M | $13.7M | $13.7M | $12.2M | $41.3M | $13.0M |
| Deferred income taxes | -$1.9M | $447.0K | -$1.1M | -$701.0K | -$170.0K | -$1.2M | -$8.6M | -$322.0K |
| Change in accounts receivable | — | — | — | — | — | — | $547.0K | $83.0K |
| Purchases of investments | $490.4M | $505.7M | $60.9M | $74.7M | $88.8M | $131.2M | $66.4M | $164.1M |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Operating income | -$373.1M | -$279.3M | -$214.1M | -$129.1M | -$79.0M |
| Net income | -$345.9M | -$234.3M | -$182.4M | -$125.4M | -$78.9M |
| EPS (diluted) | $-4.36 | $-3.01 | $-2.73 | $-2.06 | $-1.77 |
| EPS (basic) | $-4.36 | $-3.01 | $-2.73 | $-2.06 | $-1.77 |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $633.2M | $798.1M | $964.8M | $754.1M | $572.0M |
| Total liabilities | $51.4M | $43.2M | $36.9M | $32.6M | $22.0M |
| Stockholders' equity | $581.8M | $754.9M | $927.9M | $721.5M | $550.0M |
| Total current assets | $560.6M | $635.3M | $645.0M | $600.3M | $559.0M |
| Total current liabilities | $41.8M | $35.6M | $27.3M | $22.7M | $14.3M |
| Cash & equivalents | $199.2M | $142.7M | $148.6M | $57.2M | $175.7M |
| Marketable securities (current) | $349.7M | $484.2M | $489.4M | $534.8M | $376.1M |
| Accounts receivable | — | $1.5M | $874.0K | $986.0K | $2.8M |
| Marketable securities (non-current) | $37.2M | $127.5M | $292.8M | $128.7M | $0 |
| Property, plant & equipment | $8.7M | $10.3M | $9.7M | $6.5M | $4.5M |
| Deferred revenue (current) | — | — | — | — | — |
| Short-term debt | — | — | — | — | — |
| Long-term debt | — | — | — | — | — |
| Other non-current liabilities | $3.2M | $0 | — | — | — |
| Common stock & paid-in capital | $1.60B | $1.46B | $1.44B | $1.07B | $783.2M |
| Retained earnings | -$1.25B | -$899.5M | -$665.1M | -$482.7M | -$357.4M |
| Accumulated other comprehensive income (loss) | $335.0K | -$1.6M | -$77.0K | -$3.0M | -$990.0K |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$279.1M | -$181.4M | -$151.1M | -$101.0M | -$69.5M |
| Investing cash flow | $218.0M | $165.0M | -$111.4M | -$293.4M | -$246.8M |
| Financing cash flow | $117.1M | $12.1M | $353.5M | $278.5M | $447.5M |
| Free cash flow | -$279.9M | -$184.5M | -$156.7M | -$103.9M | -$71.6M |
| Capital expenditures | $799.0K | $3.1M | $5.6M | $2.9M | $2.0M |
| Depreciation & amortization | — | — | — | — | — |
| Share-based compensation | $53.7M | $50.7M | $32.4M | $20.4M | $10.0M |
| Deferred income taxes | -$3.2M | -$8.9M | -$292.0K | -$44.0K | $58.0K |
| Change in accounts receivable | — | $614.0K | -$130.0K | -$1.8M | $459.0K |
| Purchases of investments | $355.7M | $532.3M | $793.9M | $551.1M | $389.5M |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding XENE as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Source: Business Quant SEC Form 13F · report period 2026-06-30 · 30 filers
Held by These Filers72.7%
Shares Outstanding99,609,804
| Filer | Shares | Value | % Out | Qtr Change | Filed |
|---|---|---|---|---|---|
| FMR LLC | 9,647,998 | $582.4M | 9.69% | -10.8% | 2026-08-13 |
| BlackRock, Inc. | 7,522,482 | $454.1M | 7.55% | +33.4% | 2026-08-07 |
| Avoro Capital Advisors LLC | 5,777,777 | $348.7M | 5.80% | +0.0% | 2026-08-14 |
| Polar Capital Holdings Plc | 4,570,556 | $275.9M | 4.59% | +3.8% | 2026-08-14 |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 4,418,557 | $266.7M | 4.44% | -1.6% | 2026-08-14 |
| Jupiter Topco LLC | 4,186,519 | $252.7M | 4.20% | +0.0% | 2026-08-14 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 3,248,219 | $196.1K | 3.26% | +144.3% | 2026-08-14 |
| Jpmorgan Chase & Co | 2,617,360 | $157.4M | 2.63% | +36.1% | 2026-08-12 |
| Capital International Investors | 2,361,639 | $142.5M | 2.37% | -11.7% | 2026-08-07 |
| T. Rowe Price Investment Management, Inc. | 2,168,581 | $130.9K | 2.18% | +127.8% | 2026-08-14 |
| State Street Corp | 1,969,629 | $118.9M | 1.98% | +14.5% | 2026-08-07 |
| TWO SIGMA INVESTMENTS, LP | 1,642,848 | $99.2M | 1.65% | +171.1% | 2026-08-07 |
| DEERFIELD MANAGEMENT COMPANY, L.P. | 1,615,696 | $97.5M | 1.62% | +0.0% | 2026-08-14 |
| Affinity Asset Advisors, LLC | 1,595,000 | $96.3M | 1.60% | -4.8% | 2026-08-13 |
| ALLIANCEBERNSTEIN L.P. | 1,562,276 | $90.8M | 1.57% | +11.3% | 2026-08-14 |
| WESTFIELD CAPITAL MANAGEMENT CO LP | 1,507,294 | $91.0M | 1.51% | +7.5% | 2026-08-12 |
| Franklin Templeton Inc | 1,437,712 | $86.8M | 1.44% | +12.3% | 2026-08-04 |
| WELLINGTON MANAGEMENT GROUP LLP | 1,425,492 | $86.0M | 1.43% | -70.5% | 2026-08-14 |
| CITADEL ADVISORS LLC | 1,401,242 | $84.6M | 1.41% | -47.2% | 2026-08-14 |
| GEODE CAPITAL MANAGEMENT, LLC | 1,370,114 | $82.7M | 1.38% | +25.4% | 2026-08-12 |
| Siren, L.L.C. | 1,318,564 | $79.6M | 1.32% | +0.0% | 2026-08-13 |
| BNP Paribas Asset Management Holding S.A. | 1,290,731 | $77.9M | 1.30% | -3.8% | 2026-08-12 |
| Pictet Asset Management Holding SA | 1,187,723 | $71.6M | 1.19% | +74.7% | 2026-07-30 |
| BRAIDWELL LP | 1,131,452 | $68.3M | 1.14% | -15.5% | 2026-08-14 |
| Nuveen, LLC | 993,126 | $59.9M | 1.00% | +297.2% | 2026-08-11 |
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2026-03-09 to 2026-10-15
Recent transactions
- Insiders have net bought 25,420 shares over the last 182 days, across 2 purchases and 5 sales.
- Most recent: Kelly Thomas Patrick (Chief Financial Officer) — Option exercise of 7,500 shares on 2026-10-15.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)45,000 sh(2 txns)
Sales (open market)19,580 sh(5 txns)
Net Shares+25,420
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Kelly Thomas Patrick | Chief Financial Officer | Option exercise | 2026-10-15 | 7,500 |
| MORTIMER IAN | PRESIDENT & CEO | Open market purchase | 2026-09-30 | 30,000 |
| Svoronos Dawn | Reporting person | Option exercise | 2026-09-01 | 5,144 |
| KENNEY CHRISTOPHER JOHN | Chief Medical Officer | Open market sale | 2026-08-28 | 6,368 |
| GANNON STEVEN | Reporting person | Open market sale | 2026-08-11 | 10,000 |
| PATOU GARY | Reporting person | Open market sale | 2026-06-05 | 1,322 |
| Cannon Gillian | Reporting person | Open market sale | 2026-06-05 | 1,190 |
| Machado Patrick | Reporting person | Option exercise | 2026-06-01 | 2,645 |
| Gover Justin D. | Reporting person | Option exercise | 2026-06-01 | 2,645 |
| GAROFALO ELIZABETH A. | Reporting person | Option exercise | 2026-06-01 | 2,645 |
| DiFabio Andrea | Chief Legal Officer | Open market sale | 2026-03-13 | 1,342 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-10-15 | Kelly Thomas Patrick | Chief Financial Officer | Option exercise | 7,500 | — |
| 2026-09-30 | Kelly Thomas Patrick | Chief Financial Officer | Open market purchase | 15,000 | $37.32 |
| 2026-09-30 | MORTIMER IAN | PRESIDENT & CEO | Open market purchase | 30,000 | $37.38 |
| 2026-09-01 | Svoronos Dawn | Reporting person | Option exercise | 5,144 | $8.15 |
| 2026-08-28 | KENNEY CHRISTOPHER JOHN | Chief Medical Officer | Open market sale | 6,368 | $60.17 |
| 2026-08-28 | KENNEY CHRISTOPHER JOHN | Chief Medical Officer | Open market sale | 700 | $60.98 |
| 2026-08-11 | GANNON STEVEN | Reporting person | Open market sale | 10,000 | $64.06 |
| 2026-06-05 | PATOU GARY | Reporting person | Open market sale | 1,322 | $53.14 |
| 2026-06-05 | Cannon Gillian | Reporting person | Open market sale | 1,190 | $53.14 |
| 2026-06-01 | PATOU GARY | Reporting person | Option exercise | 2,645 | — |
| 2026-06-01 | Machado Patrick | Reporting person | Option exercise | 2,645 | — |
| 2026-06-01 | Gover Justin D. | Reporting person | Option exercise | 2,645 | — |
| 2026-06-01 | GAROFALO ELIZABETH A. | Reporting person | Option exercise | 2,645 | — |
| 2026-06-01 | GANNON STEVEN | Reporting person | Option exercise | 2,645 | — |
| 2026-06-01 | GANNON STEVEN | Reporting person | Tax withholding | 1,416 | $53.41 |
| 2026-06-01 | Cannon Gillian | Reporting person | Option exercise | 2,645 | — |
| 2026-06-01 | Svoronos Dawn | Reporting person | Option exercise | 2,645 | — |
| 2026-06-01 | Svoronos Dawn | Reporting person | Tax withholding | 1,416 | $53.41 |
| 2026-05-12 | GANNON STEVEN | Reporting person | Option exercise | 3,500 | $7.38 |
| 2026-03-13 | KENNEY CHRISTOPHER JOHN | Chief Medical Officer | Open market sale | 1,410 | $55.23 |
| 2026-03-13 | DiFabio Andrea | Chief Legal Officer | Open market sale | 1,342 | $55.23 |
| 2026-03-13 | MORTIMER IAN | PRESIDENT & CEO | Open market sale | 7,308 | $55.23 |
| 2026-03-12 | KENNEY CHRISTOPHER JOHN | Chief Medical Officer | Option exercise | 3,750 | — |
| 2026-03-12 | DiFabio Andrea | Chief Legal Officer | Option exercise | 3,750 | — |
| 2026-03-12 | MORTIMER IAN | PRESIDENT & CEO | Option exercise | 12,500 | — |
| 2026-03-10 | KENNEY CHRISTOPHER JOHN | Chief Medical Officer | Open market sale | 2,771 | $60.11 |
| 2026-03-10 | DiFabio Andrea | Chief Legal Officer | Open market sale | 2,607 | $60.11 |
| 2026-03-10 | MORTIMER IAN | PRESIDENT & CEO | Open market sale | 11,269 | $60.11 |
| 2026-03-09 | KENNEY CHRISTOPHER JOHN | Chief Medical Officer | Option exercise | 7,500 | — |
| 2026-03-09 | DiFabio Andrea | Chief Legal Officer | Option exercise | 7,500 | — |
| 2026-03-09 | MORTIMER IAN | PRESIDENT & CEO | Option exercise | 75,000 | $8.40 |
| 2026-03-09 | MORTIMER IAN | PRESIDENT & CEO | Open market sale | 21,791 | $58.81 |
| 2026-03-09 | MORTIMER IAN | PRESIDENT & CEO | Open market sale | 31,694 | $59.88 |
| 2026-03-09 | MORTIMER IAN | PRESIDENT & CEO | Open market sale | 21,515 | $60.49 |
| 2026-03-09 | MORTIMER IAN | PRESIDENT & CEO | Option exercise | 25,000 | $3.10 |
| 2026-03-09 | MORTIMER IAN | PRESIDENT & CEO | Open market sale | 12,479 | $59.50 |
| 2026-03-09 | MORTIMER IAN | PRESIDENT & CEO | Open market sale | 10,072 | $60.47 |
| 2026-03-09 | MORTIMER IAN | PRESIDENT & CEO | Open market sale | 2,449 | $61.26 |
| 2026-03-09 | MORTIMER IAN | PRESIDENT & CEO | Option exercise | 105,000 | $4.75 |
| 2026-03-09 | MORTIMER IAN | PRESIDENT & CEO | Open market sale | 43,348 | $59.26 |
| 2026-03-09 | MORTIMER IAN | PRESIDENT & CEO | Open market sale | 61,652 | $60.08 |
| 2026-03-09 | MORTIMER IAN | PRESIDENT & CEO | Option exercise | 65,000 | $9.44 |
| 2026-03-09 | MORTIMER IAN | PRESIDENT & CEO | Open market sale | 65,000 | $62.06 |
| 2026-03-09 | MORTIMER IAN | PRESIDENT & CEO | Option exercise | 20,000 | — |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 04:12 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-10-16 | 4 | 2026-10-15 | View on SEC.gov → |
| 2026-10-01 | 4 | 2026-09-30 | View on SEC.gov → |
| 2026-10-01 | 4 | 2026-09-30 | View on SEC.gov → |
| 2026-09-03 | 4 | 2026-09-01 | View on SEC.gov → |
| 2026-08-31 | 4 | 2026-08-28 | View on SEC.gov → |
| 2026-08-13 | 4 | 2026-08-11 | View on SEC.gov → |
| 2026-08-06 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-08-06 | 8-K | 2026-08-06 | View on SEC.gov → |
| 2026-06-08 | 4 | 2026-06-05 | View on SEC.gov → |
| 2026-06-08 | 4 | 2026-06-05 | View on SEC.gov → |
| 2026-06-03 | 4 | 2026-06-01 | View on SEC.gov → |
| 2026-06-03 | 4 | 2026-06-01 | View on SEC.gov → |
Recent news
Headlines about XENE (Xenon Pharmaceuticals Inc. Common Shares). Links open the publisher — we don’t host full articles.
-
Xenon Pharmaceuticals Inc. (XENE) Stock Price, News, Quote & History
Yahoo! Finance Canada · 2026-10-21 -
Xenon Pharmaceuticals Inc. (XENE) stock price, news, quote and history
Yahoo Finance UK · 2026-10-20 -
Xenon Pharmaceuticals Inc. (XENE) Interactive Stock Chart
Yahoo! Finance Canada · 2026-10-20 -
Inside the $1 Billion Blockbuster Opportunity Sending Rapport Therapeutics Stock Higher
Yahoo · 2026-10-20 -
XENE Jan 2028 67.500 put (XENE280121P00067500) stock price, news, quote and history
Yahoo Finance UK · 2026-10-18 -
Vesting adds 7,500 shares for Xenon Pharmaceuticals (XENE) CFO; direct holdings total 22,500.
Stock Titan · 2026-10-17 -
XENE Jan 2028 95.000 call (XENE280121C00095000) interactive stock chart
Yahoo Finance UK · 2026-10-16 -
Xenon Pharmaceuticals (XENE) Ticks Higher as Shares Trade Above Key Support - Zigzag Correction
https://www.siam.in/ · 2026-10-15
No headlines in this category right now — try “All”.